Ocugen Announces FDA Clearance for Phase 2/3 Trial of OCU410ST for Stargardt Disease

Analysis reveals significant industry trends and economic implications

Release Date

2025-06-17

Category

Clinical Trial Event

Reference

Source

Breakthrough Clinical Results

Ocugen, Inc. announced that the U.S. FDA has cleared an Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory clinical trial of OCU410ST, a modifier gene therapy for Stargardt disease. Positive Phase 1 data showed a favorable safety profile, slower lesion growth, and improved visual function. The Phase 2/3 trial will enroll 51 participants, with 34 receiving OCU410ST and 17 serving as controls. The primary objective is to evaluate the reduction in atrophic lesion size. Ocugen plans to submit a Biologics License Application (BLA) for OCU410ST in 2027.

Key Highlights

  • FDA cleared IND amendment for Phase 2/3 trial of OCU410ST for Stargardt disease.
  • Positive Phase 1 data showed favorable safety, slower lesion growth, and improved vision.
  • Phase 2/3 trial will enroll 51 participants, evaluating lesion size reduction and visual acuity.
  • BLA submission for OCU410ST is planned for 2027.

Incidence and Prevalence

Stargardt disease (STGD) is the most common inherited macular dystrophy, primarily affecting young adults. While several studies have investigated its incidence and prevalence, a definitive global estimate is challenging to pinpoint due to variations in study methodologies and populations. Furthermore, the available literature often focuses on specific regions or populations, making direct global comparisons difficult.

Incidence:

Prevalence:

Challenges in Estimating Global Burden:

Future Directions:

To obtain more precise global estimates of STGD incidence and prevalence, future research should prioritize:

In summary, while existing data provides a preliminary understanding of STGD incidence and prevalence, further research is needed to establish more accurate and representative global estimates. Standardized diagnostic criteria, large-scale studies, and increased representation from diverse populations are crucial for achieving this goal.

Study Design Parameters

Several studies have explored the progression of Stargardt disease and identified potential outcome measures for clinical trials. Here's a summary of study design parameters and endpoints used in key trials:

Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies:

  • Objective: Document the natural course of Stargardt disease and identify appropriate outcome measures for clinical trials.
  • Methods: Prospective, multicenter study using fundus autofluorescence imaging, optical coherence tomography (OCT), and microperimetry.
  • Endpoints:

  • Fundus autofluorescence: Measurement of areas of definitely decreased autofluorescence (DDAF) and questionably decreased autofluorescence (QDAF).

  • OCT: Assessment of ellipsoid zone (EZ) loss width and area.

  • Microperimetry: Evaluation of mean retinal sensitivity (MS) and the number of points with normal sensitivity, relative scotoma, or deep scotoma.

Progression of Stargardt Disease Study:

  • Objective: Describe the yearly progression rate of atrophic lesions.
  • Design: Multicenter retrospective cohort study.
  • Participants: 251 patients with disease-causing variants in ABCA4, of which 215 had at least two gradable fundus autofluorescence images with atrophic lesions.
  • Endpoint: Yearly rate of progression of atrophic lesions measured by fundus autofluorescence (DDAF and QDAF).
  • Results: Mean progression of DDAF was 0.51 mm^2/year, and total decreased autofluorescence was 0.35 mm^2/year. Progression rates depended on initial lesion size.

Natural History Study of Stargardt Disease Type 4:

  • Objective: Describe the design and baseline characteristics of patients with STGD4.
  • Design: Multicenter, prospective natural history study.
  • Participants: 15 patients with disease-causing variants in PROM1.
  • Methods: Best-corrected visual acuity, OCT, fundus autofluorescence, mesopic and scotopic microperimetry.
  • Endpoints: Area of DDAF, mean retinal sensitivity.

Study on Late-Onset Stargardt Disease:

  • Objective: Describe the natural history and demonstrate the accuracy of retinal pigment epithelium (RPE) atrophy progression as an outcome measure.
  • Design: Retrospective cohort study.
  • Participants: 47 patients with late-onset Stargardt disease (age of onset 45 years).
  • Endpoint: RPE atrophy progression measured on fundus autofluorescence and near-infrared reflectance imaging.
  • Results: Mean RPE atrophy progression was 0.22 mm/year.

Study on EZ Loss in Childhood-Onset STGD1:

  • Objective: Evaluate the reliability of EZ loss measurements from SD-OCT and track disease progression.
  • Participants: 46 children with molecularly confirmed STGD1.
  • Endpoint: Annual rate of EZ width and area loss measured by SD-OCT.
  • Results: Mean annual rate of transverse EZ loss was 279.5 m/year, and mean rate of EZ area loss was 1.20 mm^2/year. Area of EZ loss was more sensitive than transverse EZ width loss.

Study on Impact of Decreased AF on Visual Acuity:

  • Objective: Investigate the impact of decreased AF areas on visual acuity in recent-onset STGD1.
  • Design: Prospective, international, multicenter observational study.
  • Participants: 64 patients with recent-onset STGD1 (symptom onset 2 years before the first visit).
  • Endpoints: Rate of change in visual acuity, rate of change of DDAF, QDAF, and total decreased AF area.
  • Results: Visual acuity change was not significantly associated with changes in DDAF, QDAF, or total decreased AF area. DDAF growth rate depended on initial lesion size.

In summary, fundus autofluorescence, OCT, and microperimetry are key outcome measures used in Stargardt disease trials. DDAF area, EZ loss, and mean retinal sensitivity are frequently used quantitative endpoints. Visual acuity is also assessed, but its rate of change may not be directly correlated with changes in atrophic lesion size in recent-onset disease.

Drug used in other indications

OCU410ST, also known as sepofarsen, is primarily known for its trials in Stargardt disease (STGD1), a form of inherited macular degeneration. Specifically, it targets the common deep-intronic c.2991+1655A>G mutation in the CEP290 gene, which is associated with a form of Leber congenital amaurosis (LCA). LCA is also an inherited retinal dystrophy, but unlike Stargardt disease, it presents at birth or in early infancy.

Sepofarsen is an antisense oligonucleotide (ASO) designed to modulate pre-messenger RNA splicing. In the context of LCA caused by the c.2991+1655A>G mutation, sepofarsen aims to correct the aberrant splicing of the CEP290 gene, thereby restoring normal protein function and potentially improving vision.

The intervention model for trials involving sepofarsen typically involves intravitreal injections of the ASO. This delivery method allows the drug to reach the retina, where the CEP290 protein plays a crucial role in photoreceptor function. Clinical trials have demonstrated the safety and durability of sepofarsen, with early efficacy data suggesting potential visual improvements in some patients. However, further research is needed to fully assess the long-term efficacy and potential variability in clinical response, particularly in patients who are compound heterozygotes for CEP290 mutations.

Stay Ahead with More Insights

Log on to knolens for more information.